Clinical Trial Update: Evaluation of the Hypnotic Properties of Zolpidem-MR 12.5 mg and Zolpidem 10 mg Marketed Product Compared to Placebo in Patients With Primary Insomnia [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Zolpidem-MR 12.5 mg and Zolpidem 10 mg to placebo in adults with primary insomnia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insomnia

Drugs mentioned

• Zolpidem 10 mg (zolpidem)
• Zolpidem-MR 12.5 mg (zolpidem)

Snippet

Sponsor: Sanofi | Conditions: Sleep Initiation and Maintenance Disorders | Phase 3 | Status: COMPLETED